Key Takeaways
Brower reinforces two strong early defenses against class actions targeting OTC product labeling and marketing. First, plaintiffs alleging product contamination must plead product-specific testing linked to their own purchases; generalized testing or studies will not suffice. Second, omission-based claims are expressly preempted where the FDA’s governing monograph does not require the disclosure plaintiffs seek.
Brower extends to heavy metals claims against Colgate toothpastes the same reasoning we previously wrote about in PFAS consumer class actions, and pairs it with an express preemption ruling rejecting omission-based claims. Brower v. Colgate-Palmolive Co., 2026 WL 1831253 (S.D.N.Y. June 25, 2026). The decision provides additional authority for early dismissal of similar claims targeting FDA-regulated over-the-counter (“OTC”) products.